Medications, Renal Function, and Kidney Injury: A Complex Interplay, Wherein Prevention Is Easier Than Cure!

Journal of the American Medical Directors Association

Volumn 15, Issue 10, 2014, Pages 692-696

  Dharmarajan, T S ^a   Davuluri, Surya ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMANTADINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ATENOLOL; AZITHROMYCIN; CILASTATIN PLUS IMIPENEM; DEXTROPROPOXYPHENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROMYCIN; GADOLINIUM; GENTAMICIN; IODINATED CONTRAST MEDIUM; MORPHINE; NADOLOL; NEUROLEPTIC AGENT; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSELTAMIVIR; PARACETAMOL; PETHIDINE; RIMANTADINE; TRAMADOL; UNINDEXED DRUG; VALACICLOVIR; VANCOMYCIN; VITAMIN;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; AGING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG INDUCED ACUTE KIDNEY INJURY; DRUG INDUCED DISEASE; DRUG METABOLISM; EDITORIAL; EVIDENCE BASED PRACTICE; HUMAN; KIDNEY FUNCTION; MAINTENANCE DRUG DOSE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTOXICITY; NURSING HOME; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; TREATMENT DURATION; CHEMICALLY INDUCED; FEMALE; MALE;

ACUTE KIDNEY INJURY; FEMALE; HUMANS; MALE; NURSING HOMES;

EID: 84927662522     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2014.07.001     Document Type: Editorial

References (72)

1. Handler S.M., Cheung P.W., Culley C.M., et al. Determining the incidence of drug-associated acute kidney injury in nursing home residents. JAm Med Dir Assoc 2014, 719-724.
2. Belloma R., Ronco C., Kellum J.A., et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212.
3. Khanal A., Peterson G.M., Castelino R.L., Jose M.D. Renal drug dosing recommendations: evaluation of product information for brands of the same drug. Intern Med J 2014, 44:591-596.
4. Garcia-Gollarte F., Baleriola-Julvez J., Ferrero-Lopez I., Cruz-Jentoft A.J. Inappropriate drug prescription at nursing home admission. JAm Med Dir Assoc 2012, 13:83.e9-83.e15.
5. Perazella M.A. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 2009, 4:1275-1283.
6. Munar M.Y., Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician 2007, 75:1487-1496.
7. Doogue M.P., Polasek T.M. Drug dosing in renal disease. Clin Biochem 2011, 32:69-73.
8. Naughton C.A. Drug-induced nephrotoxicity. Am Fam Physician 2008, 78:743-750.
9. Aitken E., Carruthers C., Gall L., et al. Acute kidney injury: Outcomes and quality of care. QJM 2013, 106:323-332.
10. Khanal A., Castelino R.L., Peterson G.M., Jose M.D. Dose adjustment guidelines for medications in patients with renal impairment: How consistent are drug information sources?. Intern Med J 2014, 44:77-85.
11. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
12. US Renal Data Systems USRDS 2009 Annual Data Report: Atlas of CKD and ESRD in the US 2009, National Institutes of Health, National Institute of diabetes and Digestive and kidney diseases, Bethesda, MD.
13. Lindeman R.D., Tobin J., Shock N.W. Longitudinal studies on the rate of decline in renal function with age. JAm Geriatr Soc 1985, 33:278-285.
14. Puyol D.R. The aging kidney. Kidney Int 1998, 54:2247-2265.
15. Epstein M. Aging and the kidney. JAm Soc Nephrol 1996, 7:1106-1122.
16. Dharmarajan T.S. The physiology of aging. Geriatric Gastroenterology 2012, 17-31. Springer, New York. 1st ed. T.S. Dharmarajan, C.S. Pitchumoni (Eds.).
17. Taffet G.E. Age related physiological changes. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine 1999, 10-23. Kendall/Hunt Publishing, Iowa. 4th ed. E.L. Cobbs, E.H. Duthie, J.B. Murphy (Eds.).
18. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
19. Levey A.S., Bosch J.P., Lewis J.B., et al. Amore accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999, 130:461-470.
20. Levey A.S., Stevens L.A., Schmid C.H., et al. Anew equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
21. Dharmarajan T.S., Yoo J., Russell R.O., Norkus E.P. Chronic kidney disease staging in community and nursing home older adults: Does the choice of cockcroft-gault, modification of diet in renal disease study, or the chronic kidney disease epidemiology collaboration initiative equations matter?. JAm Med Dir Assoc 2012, 13:151-155.
22. Moranville M.P., Jennings H.R. Implications of using modification of diet in renal disease versus Cockroft-Gault equations for renal dosing adjustments. Am J Health-Syst Pharm 2009, 66:154-161.
23. Pedone C., Corsonello A., Incalzi R.A., et al. Estimating renal function in older people: A comparison of three formulas. Age Aging 2006, 35:121-126.
24. Pequignot R., Belmin J., Chauvelier S., et al. Renal function in older hospital patients is more accurately estimated using the Cockcroft-Gault formula than the modification diet in renal disease formula. JAm Geriatr Soc 2009, 57:1638-1643.
25. Michels W.M., Grootendorst D.C., Verduijn M., et al. Performance of the Cockcroft-Gault, MDRD and new CKD-EPI formulas in relation to GFR, age and body size. Clin J Am Soc Nephrol 2010, 5:1003-1009.
26. Gault M.H., Barrett B.J. Analgesic nephropathy. Am J Kidney Dis 1998, 32:351-360.
27. Faraq A., Garg A.X., Li L., Jain A.K. Dosing errors in prescribed antibiotics for older persons with CKD: A retrospective time series analysis. Am J Kidney Dis 2014, 63:422-428.
28. Bird S.T., Etminan M., Brophy J.M., et al. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ 2013, 185:E475-E482.
29. Van Hal S.J., Peterson D.L., Lodise T.P. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013, 57:734-744.
30. Panwar B., Johnson V.A., Patel M., Balkovetz D.F. Risk of vancomycin induced nephrotoxicity in the population with chronic kidney disease. Am J Med Sci 2013, 345:396-399.
31. Cianferoni S., Deviaili A., Ocampos-Martinez E., et al. Development of acute kidney injury during continuous infusion of vancomycin in septic patient. Infection 2013, 41:811-820.
32. Tomlinson L.A., Abel G.A., Chaudhry A.N., et al. ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: A longitudinal ecological study. PLoS One 2013, 8:e78465.
33. Mazer M., Perroine J. Acetaminophen induced nephrotoxicity: Pathophysiology, clinical manifestations, and management. JMed Toxicol 2008, 4:2-6.
34. O'Riordan A., Brummell Z., Sizer E., et al. Acute kidney injury in patients admitted to a liver intensive therapy unit with paracetamol-induced hepatotoxicity. Nephrol Dial Transplant 2011, 26:3501-3508.
35. Elseviers M.M., De Broe M.E. Analgesic nephropathy: Is it caused by multi-analgesic abuse or single substance use?. Drug Saf 1999, 20:15-24.
36. Nawaz F.A., Larsen C.P., Troxell M.L. Membranous nephropathy and nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2013, 62:1012-1017.
37. Markowitz G.S., Falkowitz D.C., Isom R., et al. Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. Clin Nephrol 2003, 59:137-142.
38. Dhanvijay P., Misra A.K., Varma S.K. Diclofenac induced acute renal failure in a decompensated elderly patient. JPharmacol Pharmacother 2013, 4:155-157.
39. Moller B., Pruijm M., Adler S., et al. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis 2013, [published online ahead of print December 19, 2013]. 10.1136/annrheumdis-2013-204078.
40. Nderitu P., Doos L., Jones P.W., et al. Nonsteroidal anti-inflammatory drugs and chronic kidney disease progression: Systematic review. Fam Pract 2013, 30:247-255.
41. Smith R.L. Calcium and vitamin D supplementation in nursing home residents. JAm Med Dir Assoc 2003, 2:S24-S31.
42. Gladziwa U., Klotz U. Pharmacokinetics and pharmacodynamics of H2 receptor antagonists in patients with renal insufficiency. Clin Pharmacokinet 1993, 24:319-332.
43. Boudville N. The predictable effect that renal failure has on H2 receptor antagonists-increasing the half-life along with increasing prescribing errors. Nephrol Dial Transplant 2005, 20:2315-2317.
44. Gitlin M. Lithium and the kidney: An updated review. Drug Saf 1999, 20:231-243.
45. Cunningham J., Rodriguez M., Messo P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin Kidney J 2012, 5:139-151.
46. Wyskida K., Witkowicz J., Chudek J., Wiecek A. Daily magnesium intake and hypermagnesemia in hemodialysis patients with chronic kidney disease. JRen Nutr 2012, 22:19-26.
47. Sica D.A., Carl D., Zfass A.M. Acute phosphate nephropathy-an emerging issue. Am J Gastroenterol 2007, 102:1844-1847.
48. Markowitz G.S., Nasr S.H., Klein P., et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004, 35:675-684.
49. Abe M., Okada K., Soma M. Anti-diabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: Metabolism and clinical practice. Curr Drug Metab 2011, 12:57-69.
50. Arnouts P., Bolignano D., Nistor I., et al. Glucose lowering drugs in patients with chronic kidney disease: A narrative review on pharmacokinetic properties. Nephrol Dial Transplant 2014, 29:1284-1300.
51. Zanchi A., Lehmann R., Philippe J. Antidiabetic drugs and kidney disease. Recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Med Wkly 2012, 142:w13629.
52. Lai A., Davidson N., Galloway S.W., Thachil J. Perioperative management of patients on newer anticoagulants. Br J Surg 2014, 101:742-749.
53. Dharmarajan T.S., Sohagia A. Low-molecular-weight heparin and bleeding: How do we lower risk but maintain benefit?. Ann Intern Med 2006, 145:789-790.
54. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: How concerned should we be by the rise in serum creatinine?. JAm Geriatr Soc 2002, 50:1297-1300.
55. Navis G., Faber H.J., de Zeeuw D., de Jong P.E. ACE inhibitors and the kidney. Arisk-benefit assessment. Drug Saf 1996, 15:100-111.
56. Molnar M.Z., Kalantar-Zadeh K., Lott E.H., et al. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use and mortality in patients with chronic kidney disease. JAm Coll Cardiol 2014, 63:650-658.
57. Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993, 25:20-58.
58. Gualtierotti R., Zoppi A., Mugellini A., et al. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. Expert Opin Pharmacother 2013, 14:1875-1884.
59. He Y.M., Feng L., Huo D.M., et al. Enalapril versus losartan for adults with chronic kidney disease: A systematic review and meta-analysis. Nephrology (Carlton) 2013, 18:605-614.
60. Dwyer L.L., Han B., Woodwell D.A., Rechtsteiner E.A. Polypharmacy in nursing home residents in the United States: Results of the 2004 National Nursing Home Survey. Am J Geriatr Pharmacother 2010, 8:63-72.
61. Curhan G.C., Willett W.C., Speizer F.E., et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997, 126:497-504.
62. Tang J., Chonchol M.B. Vitamin D and kidney stone disease. Curr Opin Nephrol Hypertens 2013, 22:383-389.
63. Taylor E.N., Stampfer M.J., Curhan G.C. Dietary factors and the risk of incident kidney stones in men: New insights after 14 years of follow-up. JAm Soc Nephrol 2004, 15:3225-3232.
64. Messinger-Rapport B.J., Morley J.E., Thomas D.R., Gammack J.K. Clinical update on nursing home medicine: 2011. JAm Med Dir Assoc 2011, 12:615-626.
65. Classen D.C., Pestotnik S.L., Evans R.S., et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997, 277:301-306.
66. Ingrasciotta Y., Sultana J., Giorgiani F., et al. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: A retrospective population based study in southern Italy. PLoS One 2014, 9:e89072.
67. Beier M.T. Updated 2021 beers Criteria: What's Noteworthy and cautionary?. JAm Med Dir Assoc 2012, 13:768-769.
68. Hanlon J.T., Wang X., Handler S.M., et al. Potentially inappropriate prescribing of primarily renally cleared medications for older Veterans Affairs nursing home patients. JAm Med Dir Assoc 2011, 12:377-383.
69. Drinka P.J. Medications prescribed by specialists in nursing homes. JAm Med Dir Assoc 2008, 9:137-138.
70. Patel K., Diamantidis C., Zhan M., et al. Influence of creatinine versus GFR on NSAID prescriptions in CKD. Am J Nephrol 2012, 26:19-26.
71. The American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. JAm Geriatr Soc 2012, 60:616-631.
72. Milani R.V., Oleck S.A., Lavie C.J. Medication errors in patients with severe chronic kidney disease and acute coronary syndrome: The impact of computer-assisted decision support. Mayo Clin Proc 2011, 86:1161-1164.